Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Josting

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Transfusion|February 24, 2000
High platelet contamination in progenitor cell concentrates results in significantly lower CD34+ yield after immunoselectionM Reiser, A Draube, C Scheid, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2003
Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG)J U Rüffer, H Flechtner, P Tralls, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2001
Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosisU Rueffer, A Josting, J Franklin, et al.
Leukemia & Lymphoma|October 21, 2005
BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study GroupJ U Rüffer, V Ballova, J Glossmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)A Josting, I Kàtay, U Rueffer, et al.
Annals of Hematology|May 24, 2003
Spleen involvement in Hodgkin's lymphoma: assessment and risk profileU Rueffer, M Sieber, M Stemberg, et al.
Leukemia & Lymphoma|July 16, 2005
Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's diseaseL Smardova, A Engert, H Haverkamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2008
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trialsM Sieniawski, T Reineke, A Josting, et al.
Leukemia & Lymphoma|April 30, 1999
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphomaM Reiser, A Josting, P Dias Wickramanayake, et al.
Leukemia & Lymphoma|March 18, 2000
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Transfusion|February 24, 2000
High platelet contamination in progenitor cell concentrates results in significantly lower CD34+ yield after immunoselectionM Reiser, A Draube, C Scheid, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2003
Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG)J U Rüffer, H Flechtner, P Tralls, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2001
Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosisU Rueffer, A Josting, J Franklin, et al.
Leukemia & Lymphoma|October 21, 2005
BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study GroupJ U Rüffer, V Ballova, J Glossmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)A Josting, I Kàtay, U Rueffer, et al.
Annals of Hematology|May 24, 2003
Spleen involvement in Hodgkin's lymphoma: assessment and risk profileU Rueffer, M Sieber, M Stemberg, et al.
Leukemia & Lymphoma|July 16, 2005
Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's diseaseL Smardova, A Engert, H Haverkamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2008
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trialsM Sieniawski, T Reineke, A Josting, et al.
Leukemia & Lymphoma|April 30, 1999
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphomaM Reiser, A Josting, P Dias Wickramanayake, et al.
Leukemia & Lymphoma|March 18, 2000
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Pageof 5